{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:31:44Z","timestamp":1794558704116,"version":"4.9.1"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1184485"],"award-info":[{"award-number":["1184485"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1184485"],"award-info":[{"award-number":["1184485"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Hospital Research Foundation - Grant Fay Fuller Foundation","id":[{"id":"https:\/\/ror.org\/01bsc2n27","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Hospital Research Foundation - scholarship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute myeloid leukaemia (AML) is a highly aggressive and devastating malignancy of the bone marrow and blood. For decades, intensive chemotherapy has been the frontline treatment for AML but has yielded only poor patient outcomes as exemplified by a 5-year survival rate of &lt;\u200930%, even in younger adults. As knowledge of the molecular underpinnings of AML has advanced, so too has the development new strategies with potential to improve the treatment of AML patients. To date the most promising of these targeted agents is the BH3-mimetic venetoclax which in combination with standard of care therapies, has manageable non-haematological toxicity and exhibits impressive efficacy. However, approximately 30% of AML patients fail to respond to venetoclax-based regimens and almost all treatment responders eventually relapse. Here, we review the emerging mechanisms of intrinsic and acquired venetoclax resistance in AML and highlight recent efforts to identify novel strategies to overcome resistance to venetoclax.<\/jats:p>","DOI":"10.1038\/s41419-024-06810-7","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T10:02:27Z","timestamp":1718186547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Gus O.","family":"Nwosu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8493-9178","authenticated-orcid":false,"given":"Jason A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9527-2740","authenticated-orcid":false,"given":"Stuart M.","family":"Pitson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"6810_CR1","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41568-020-0260-3","volume":"20","author":"M Yamashita","year":"2020","unstructured":"Yamashita M, Dellorusso PV, Olson OC, Passegu\u00e9 E. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nat Rev Cancer. 2020;20:365\u201382.","journal-title":"Nat Rev Cancer"},{"key":"6810_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cell.2008.01.025","volume":"132","author":"SH Orkin","year":"2008","unstructured":"Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132:631\u201344.","journal-title":"Cell"},{"key":"6810_CR3","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.cell.2008.10.048","volume":"135","author":"A Wilson","year":"2008","unstructured":"Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135:1118\u201329.","journal-title":"Cell"},{"key":"6810_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature13038","volume":"506","author":"LI Shlush","year":"2014","unstructured":"Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328\u201333.","journal-title":"Nature"},{"key":"6810_CR5","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","volume":"366","author":"MJ Walter","year":"2012","unstructured":"Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N. Engl J Med. 2012;366:1090\u20138.","journal-title":"N. Engl J Med"},{"key":"6810_CR6","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"118","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723\u201335.","journal-title":"Blood"},{"key":"6810_CR7","doi-asserted-by":"publisher","first-page":"149ra18","DOI":"10.1126\/scitranslmed.3004315","volume":"4","author":"M Jan","year":"2012","unstructured":"Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4:149ra18.","journal-title":"Sci Transl Med"},{"key":"6810_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JohnS Welch","year":"2012","unstructured":"Welch JohnS, Ley TimothyJ, Link DanielC, Miller ChristopherA, Larson DavidE, Koboldt DanielC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264\u201378.","journal-title":"Cell"},{"key":"6810_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19119-8","volume":"11","author":"K Morita","year":"2020","unstructured":"Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, et al. Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020;11:5327.","journal-title":"Nat Commun"},{"key":"6810_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41375-018-0319-2","volume":"33","author":"N Potter","year":"2019","unstructured":"Potter N, Miraki-Moud F, Ermini L, Titley I, Vijayaraghavan G, Papaemmanuil E, et al. Single cell analysis of clonal architecture in acute myeloid leukaemia. Leukemia. 2019;33:1113\u201323.","journal-title":"Leukemia"},{"key":"6810_CR11","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1073\/pnas.1324297111","volume":"111","author":"MR Corces-Zimmerman","year":"2014","unstructured":"Corces-Zimmerman MR, Hong W-J, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6810_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","volume":"587","author":"LA Miles","year":"2020","unstructured":"Miles LA, Bowman RL, Merlinsky TR, Csete IS, Ooi AT, Durruthy-Durruthy R, et al. Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020;587:477\u201382.","journal-title":"Nature"},{"key":"6810_CR13","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","volume":"129","author":"D Thomas","year":"2017","unstructured":"Thomas D, Majeti R. Biology and relevance of human acute myeloid leukemia stem cells. Blood. 2017;129:1577\u201385.","journal-title":"Blood"},{"key":"6810_CR14","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood-2011-06-364182","volume":"119","author":"JM Gerber","year":"2012","unstructured":"Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, et al. A clinically relevant population of leukemic CD34+CD38\u2212 cells in acute myeloid leukemia. Blood. 2012;119:3571\u20137.","journal-title":"Blood"},{"key":"6810_CR15","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"6810_CR16","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2009.813","volume":"301","author":"J Koreth","year":"2009","unstructured":"Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301:2349\u201361.","journal-title":"JAMA"},{"key":"6810_CR17","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","volume":"361","author":"HF Fernandez","year":"2009","unstructured":"Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl J Med. 2009;361:1249\u201359.","journal-title":"N. Engl J Med"},{"key":"6810_CR18","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1038\/s41375-018-0034-z","volume":"32","author":"M Rothenberg-Thurley","year":"2017","unstructured":"Rothenberg-Thurley M, Amler S, Goerlich D, Kohnke T, Konstandin NP, Schneider S, et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2017;32:1598\u2013608.","journal-title":"Leukemia"},{"key":"6810_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","volume":"110","author":"G Tamamyan","year":"2017","unstructured":"Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, et al. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017;110:20\u201334.","journal-title":"Crit Rev Oncol Hematol"},{"key":"6810_CR20","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","volume":"97","author":"B Oran","year":"2012","unstructured":"Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97:1916\u201324.","journal-title":"Haematologica"},{"key":"6810_CR21","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/leu.2014.216","volume":"29","author":"RB Walter","year":"2015","unstructured":"Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia. 2015;29:770\u20135.","journal-title":"Leukemia"},{"key":"6810_CR22","first-page":"3874","volume":"130","author":"M Dennis","year":"2017","unstructured":"Dennis M, Hills RK, Russell NH, Copland M, Thomas I, McMullin MFF, et al. An evaluation of 17 years of low dose cytarabine as therapy for AML patients not fit for intensive treatment, including patients with adverse cytogenetics, shows improving survival, potential underutilisation and highlights the need for new therapy. Blood. 2017;130:3874.","journal-title":"Blood"},{"key":"6810_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2217\/fon-2022-1286","volume":"19","author":"M Heuser","year":"2023","unstructured":"Heuser M, Fernandez C, Hauch O, Klibanov OM, Chaudhary T, Rives V. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review. Future Oncol. 2023;19:789\u2013810.","journal-title":"Future Oncol"},{"key":"6810_CR24","doi-asserted-by":"crossref","unstructured":"Yang X, Wong MPM, Ng RK. Aberrant DNA methylation in acute myeloid leukemia and its clinical implications. Int J Mol Sci. 2019;20:4576.","DOI":"10.3390\/ijms20184576"},{"key":"6810_CR25","doi-asserted-by":"publisher","first-page":"a026948","DOI":"10.1101\/cshperspect.a026948","volume":"7","author":"T Sato","year":"2017","unstructured":"Sato T, Issa JJ, Kropf P. DNA hypomethylating drugs in cancer therapy. Cold Spring Harb Perspect Med. 2017;7:a026948.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"6810_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-017-0363-4","volume":"12","author":"C Gardin","year":"2017","unstructured":"Gardin C, Dombret H. Hypomethylating agents as a therapy for AML. Curr Hematol Malig Rep. 2017;12:1\u201310.","journal-title":"Curr Hematol Malig Rep"},{"key":"6810_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts. Blood 2015;126:291\u20139.","journal-title":"Blood"},{"key":"6810_CR28","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670\u20137.","journal-title":"J Clin Oncol"},{"key":"6810_CR29","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Cancer Genome Atlas Research Network.","year":"2013","unstructured":"Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl J Med. 2013;368:2059\u201374.","journal-title":"N. Engl J Med"},{"key":"6810_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172641","volume":"862","author":"A Shimada","year":"2019","unstructured":"Shimada A. Hematological malignancies and molecular targeting therapy. Eur J Pharm. 2019;862:172641.","journal-title":"Eur J Pharm"},{"key":"6810_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H D\u00f6hner","year":"2021","unstructured":"D\u00f6hner H, Wei AH, L\u00f6wenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18:577\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"6810_CR32","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1042\/BST20230017","volume":"51","author":"E Gruber","year":"2023","unstructured":"Gruber E, Kats LM. The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches. Biochem Soc Trans. 2023;51:1675\u201386.","journal-title":"Biochem Soc Trans"},{"key":"6810_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00911-w","volume":"13","author":"NJ Short","year":"2023","unstructured":"Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023;13:142.","journal-title":"Blood Cancer J"},{"key":"6810_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani F, Collavin L, Del Sal G. Mutant p53 as a guardian of the cancer cell. Cell Death Differ. 2019;26:199\u2013212.","journal-title":"Cell Death Differ"},{"key":"6810_CR35","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"6810_CR36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/bjc.2017.281","volume":"117","author":"PA Cassier","year":"2017","unstructured":"Cassier PA, Castets M, Belhabri A, Vey N. Targeting apoptosis in acute myeloid leukaemia. Br J Cancer. 2017;117:1089.","journal-title":"Br J Cancer"},{"key":"6810_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"key":"6810_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6810_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0092-8674(00)81589-5","volume":"94","author":"X Luo","year":"1998","unstructured":"Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 1998;94:481\u201390.","journal-title":"Cell"},{"key":"6810_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/cdd.2017.161","volume":"25","author":"JM Adams","year":"2018","unstructured":"Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25:27\u201336.","journal-title":"Cell Death Differ"},{"key":"6810_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.semcdb.2017.04.001","volume":"72","author":"RW Birkinshaw","year":"2017","unstructured":"Birkinshaw RW, Czabotar PE. The BCL-2 family of proteins and mitochondrial outer membrane permeabilisation. Semin Cell Dev Biol. 2017;72:152\u201362.","journal-title":"Semin Cell Dev Biol"},{"key":"6810_CR42","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","volume":"34","author":"D Merino","year":"2018","unstructured":"Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the trail for new cancer medicines. Cancer Cell. 2018;34:879\u201391.","journal-title":"Cancer Cell"},{"key":"6810_CR43","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nature03579","volume":"435","author":"T Oltersdorf","year":"2005","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677\u201381.","journal-title":"Nature"},{"key":"6810_CR44","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421\u20138.","journal-title":"Cancer Res"},{"key":"6810_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl J Med. 2016;374:311\u201322.","journal-title":"N. Engl J Med"},{"key":"6810_CR46","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149\u201359.","journal-title":"Lancet Oncol"},{"key":"6810_CR47","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1200\/JCO.21.02188","volume":"40","author":"CN Harrison","year":"2022","unstructured":"Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, et al. Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: Phase II safety and efficacy. J Clin Oncol. 2022;40:1671\u201380.","journal-title":"J Clin Oncol"},{"key":"6810_CR48","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","volume":"128","author":"KD Mason","year":"2007","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173\u201386.","journal-title":"Cell"},{"key":"6810_CR49","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202.","journal-title":"Nat Med"},{"key":"6810_CR50","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138:1120\u201336.","journal-title":"Blood"},{"key":"6810_CR51","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/sj.leu.2401573","volume":"13","author":"M Andreeff","year":"1999","unstructured":"Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999;13:1881\u201392.","journal-title":"Leukemia"},{"key":"6810_CR52","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362\u201375.","journal-title":"Cancer Discov"},{"key":"6810_CR53","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"6810_CR54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/10428194.2014.910657","volume":"56","author":"JM Bogenberger","year":"2015","unstructured":"Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56:226\u20139.","journal-title":"Leuk Lymphoma"},{"key":"6810_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"6810_CR56","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"6810_CR57","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"6810_CR58","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2022;40:4048\u201359.","journal-title":"J Clin Oncol"},{"key":"6810_CR59","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, et al. Venetoclax plus 3\u2009+\u20097 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022;9:e415\u2013e24.","journal-title":"Lancet Haematol"},{"key":"6810_CR60","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, et al. A phase Ib\/II study of ivosidenib with venetoclax\u00b1azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023;4:276\u201393.","journal-title":"Blood Cancer Discov"},{"key":"6810_CR61","doi-asserted-by":"publisher","first-page":"380","DOI":"10.20517\/cdr.2021.125","volume":"5","author":"F Ong","year":"2022","unstructured":"Ong F, Kim K, Konopleva MY. Venetoclax resistance: mechanistic insights and future strategies. Cancer Drug Resist. 2022;5:380.","journal-title":"Cancer Drug Resist"},{"key":"6810_CR62","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.18632\/oncotarget.3275","volume":"6","author":"D Chiron","year":"2015","unstructured":"Chiron D, Dousset C, Brosseau C, Touzeau C, Maiga S, Moreau P, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6:8750\u20139.","journal-title":"Oncotarget"},{"key":"6810_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.","journal-title":"Cell Death Dis"},{"key":"6810_CR64","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2019004326","volume":"136","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kielbassa K, Ter Burg J, Bax DJC, Fernandes SM, Borst J, et al. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020;136:2918\u201326.","journal-title":"Blood"},{"key":"6810_CR65","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","volume":"1","author":"KD Jayappa","year":"2017","unstructured":"Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1:933\u201346.","journal-title":"Blood Adv"},{"key":"6810_CR66","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15:1132\u201344.","journal-title":"Mol Cancer Ther"},{"key":"6810_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3383-5","volume":"17","author":"SK Tahir","year":"2017","unstructured":"Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17:399.","journal-title":"BMC Cancer"},{"key":"6810_CR68","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"SP Glaser","year":"2012","unstructured":"Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26:120\u20135.","journal-title":"Genes Dev"},{"key":"6810_CR69","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1172\/JCI39964","volume":"120","author":"Z Xiang","year":"2010","unstructured":"Xiang Z, Luo H, Payton JE, Cain J, Ley TJ, Opferman JT, et al. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest. 2010;120:2109\u201318.","journal-title":"J Clin Invest"},{"key":"6810_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/srep27696","volume":"6","author":"KH Lin","year":"2016","unstructured":"Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, et al. Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci Rep. 2016;6:27696.","journal-title":"Sci Rep"},{"key":"6810_CR71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","volume":"7","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H, et al. Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. Signal Transduct Target Ther. 2022;7:51.","journal-title":"Signal Transduct Target Ther"},{"key":"6810_CR72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","volume":"11","author":"Y Xu","year":"2022","unstructured":"Xu Y, Ye H. Progress in understanding the mechanisms of resistance to BCL-2 inhibitors. Exp Hematol Oncol. 2022;11:31.","journal-title":"Exp Hematol Oncol"},{"key":"6810_CR73","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1182\/blood.2022016090","volume":"141","author":"DM Moujalled","year":"2023","unstructured":"Moujalled DM, Brown FC, Chua CC, Dengler MA, Pomilio G, Anstee NS, et al. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia. Blood. 2023;141:634\u201344.","journal-title":"Blood"},{"key":"6810_CR74","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","volume":"18","author":"VJN Bykov","year":"2018","unstructured":"Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89\u2013102.","journal-title":"Nat Rev Cancer"},{"key":"6810_CR75","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3324\/haematol.2018.205013","volume":"104","author":"KT Prochazka","year":"2019","unstructured":"Prochazka KT, Pregartner G, R\u00fccker FG, Heitzer E, Pabst G, W\u00f6lfler A, et al. Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica. 2019;104:516.","journal-title":"Haematologica"},{"key":"6810_CR76","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.3390\/cancers14143456","volume":"14","author":"MS Griffioen","year":"2022","unstructured":"Griffioen MS, de Leeuw DC, Janssen JJWM, Smit L. Targeting acute myeloid leukemia with venetoclax; biomarkers for sensitivity and rationale for venetoclax-based combination therapies. Cancers. 2022;14:3456.","journal-title":"Cancers"},{"key":"6810_CR77","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"6810_CR78","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood.2020010167","volume":"137","author":"R Thijssen","year":"2021","unstructured":"Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, et al. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021;137:2721\u201335.","journal-title":"Blood"},{"key":"6810_CR79","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2019Alessandro A, et al. The TP53 apoptotic network Is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9:910\u201325.","journal-title":"Cancer Discov"},{"key":"6810_CR80","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Glytsou C, Zhou H, Narang S, Reyna DE, Lopez A, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019;9:890\u2013909.","journal-title":"Cancer Discov"},{"key":"6810_CR81","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","volume":"34","author":"CL Jones","year":"2018","unstructured":"Jones CL, Stevens BM, D\u2019Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34:724\u201340 e4.","journal-title":"Cancer Cell"},{"key":"6810_CR82","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D\u2019Alessandro A, Winters A, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1:1176\u201387.","journal-title":"Nat Cancer"},{"key":"6810_CR83","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21:178\u201384.","journal-title":"Nat Med"},{"key":"6810_CR84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol. 2021;14:67.","journal-title":"J Hematol Oncol"},{"key":"6810_CR85","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477.","journal-title":"Nature"},{"key":"6810_CR86","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1182\/blood-2018-06-859405","volume":"132","author":"MS Brennan","year":"2018","unstructured":"Brennan MS, Chang C, Tai L, Lessene G, Strasser A, Dewson G, et al. Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use. Blood. 2018;132:1573\u201383.","journal-title":"Blood"},{"key":"6810_CR87","doi-asserted-by":"publisher","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","volume":"63","author":"Z Szlavik","year":"2020","unstructured":"Szlavik Z, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, et al. Discovery of S64315, a potent and selective Mcl-1 inhibitor. J Med Chem. 2020;63:13762\u201395.","journal-title":"J Med Chem"},{"key":"6810_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-2646-2","volume":"11","author":"N Mukherjee","year":"2020","unstructured":"Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, et al. MCL1 inhibitors S63845\/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020;11:1\u201314.","journal-title":"Cell Death Dis"},{"key":"6810_CR89","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8:1582\u201397.","journal-title":"Cancer Discov"},{"key":"6810_CR90","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1158\/1538-7445.AM2020-6218","volume":"80","author":"S Caenepeel","year":"2020","unstructured":"Caenepeel S, Karen R, Belmontes B, Verlinsky A, Tan H, Yang YJ, et al. Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor. Cancer Res. 2020;80:6218.","journal-title":"Cancer Res"},{"key":"6810_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100672","volume":"44","author":"A Wei","year":"2020","unstructured":"Wei A, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, et al. Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Rev. 2020;44:100672.","journal-title":"Blood Rev"},{"key":"6810_CR92","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1101\/gad.215871.113","volume":"27","author":"RL Thomas","year":"2013","unstructured":"Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27:1365\u201377.","journal-title":"Genes Dev"},{"key":"6810_CR93","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1101\/gad.215855.113","volume":"27","author":"X Wang","year":"2013","unstructured":"Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, et al. Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev. 2013;27:1351\u201364.","journal-title":"Genes Dev"},{"key":"6810_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07551-w","volume":"9","author":"AE Tron","year":"2018","unstructured":"Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341.","journal-title":"Nat Commun"},{"key":"6810_CR95","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.3390\/cancers14143330","volume":"14","author":"RD Parrondo","year":"2022","unstructured":"Parrondo RD, Paulus A, Ailawadhi S. Updates in the Use of BCL-2-family small molecule inhibitors for the treatment of relapsed\/refractory multiple myeloma. Cancers. 2022;14:3330.","journal-title":"Cancers"},{"key":"6810_CR96","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ijbiomac.2021.07.166","volume":"187","author":"P Mittal","year":"2021","unstructured":"Mittal P, Singh S, Sinha R, Shrivastava A, Singh A, Singh IK. Myeloid cell leukemia 1 (MCL-1): structural characteristics and application in cancer therapy. Int J Biol Macromol. 2021;187:999\u20131018.","journal-title":"Int J Biol Macromol"},{"key":"6810_CR97","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","volume":"27","author":"VV Senichkin","year":"2020","unstructured":"Senichkin VV, Streletskaia AY, Gorbunova AS, Zhivotovsky B, Kopeina GS. Saga of Mcl-1: regulation from transcription to degradation. Cell Death Differ. 2020;27:405\u201319.","journal-title":"Cell Death Differ"},{"key":"6810_CR98","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1182\/blood-2014-10-605584","volume":"125","author":"LF Peterson","year":"2015","unstructured":"Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, et al. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 2015;125:3588\u201397.","journal-title":"Blood"},{"key":"6810_CR99","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2019.03.046","volume":"453","author":"H Akiyama","year":"2019","unstructured":"Akiyama H, Umezawa Y, Ishida S, Okada K, Nogami A, Miura O. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress. Cancer Lett. 2019;453:84\u201394.","journal-title":"Cancer Lett"},{"key":"6810_CR100","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/13543784.2019.1678583","volume":"28","author":"DJ Lee","year":"2019","unstructured":"Lee DJ, Zeidner JF. Cyclin-dependent kinase (CDK) 9 and 4\/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach. Expert Opin Investig Drugs. 2019;28:989\u20131001.","journal-title":"Expert Opin Investig Drugs"},{"key":"6810_CR101","doi-asserted-by":"publisher","first-page":"107206","DOI":"10.18632\/oncotarget.22284","volume":"8","author":"J Bogenberger","year":"2017","unstructured":"Bogenberger J, Whatcott C, Hansen N, Delman D, Shi C-X, Kim W, et al. Combined venetoclax and alvocidib in acute myeloid leukemia. Oncotarget. 2017;8:107206.","journal-title":"Oncotarget"},{"key":"6810_CR102","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/hon.3159","volume":"41","author":"BA Jonas","year":"2023","unstructured":"Jonas BA, Hou J-Z, Roboz GJ, Alvares CL, Jeyakumar D, Edwards JR, et al. A phase 1b study of venetoclax and alvocidib in patients with relapsed\/refractory acute myeloid leukemia. Hematol Oncol. 2023;41:743\u201352.","journal-title":"Hematol Oncol"},{"key":"6810_CR103","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-20-2649","volume":"27","author":"JF Zeidner","year":"2021","unstructured":"Zeidner JF, Lee DJ, Frattini M, Fine GD, Costas J, Kolibaba K, et al. Phase I study of alvocidib followed by 7+3 (cytarabine + daunorubicin) in newly diagnosed acute myeloid leukemia. Clin Cancer Res. 2021;27:60\u20139.","journal-title":"Clin Cancer Res"},{"key":"6810_CR104","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010;9:2344\u201353.","journal-title":"Mol Cancer Ther"},{"key":"6810_CR105","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","volume":"76","author":"A Baker","year":"2016","unstructured":"Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, et al. The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia. Cancer Res. 2016;76:1158\u201369.","journal-title":"Cancer Res"},{"key":"6810_CR106","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1038\/leu.2015.99","volume":"29","author":"L Li","year":"2015","unstructured":"Li L, Pongtornpipat P, Tiutan T, Kendrick SL, Park S, Persky DO, et al. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015;29:1702\u201312.","journal-title":"Leukemia"},{"key":"6810_CR107","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","volume":"63","author":"B Barlaam","year":"2020","unstructured":"Barlaam B, Casella R, Cidado J, Cook C, De Savi C, Dishington A, et al. Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies. J Med Chem. 2020;63:15564\u201390.","journal-title":"J Med Chem"},{"key":"6810_CR108","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, et al. AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clin Cancer Res. 2020;26:922\u201334.","journal-title":"Clin Cancer Res"},{"key":"6810_CR109","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1182\/blood-2012-08-447441","volume":"122","author":"D Thomas","year":"2013","unstructured":"Thomas D, Powell JA, Vergez F, Segal DH, Nguyen N-Y, Baker A, et al. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood 2013;122:738\u201348.","journal-title":"Blood"},{"key":"6810_CR110","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1182\/blood.2021013277","volume":"139","author":"AC Lewis","year":"2022","unstructured":"Lewis AC, Pope VS, Tea MN, Li M, Nwosu GO, Nguyen TM, et al. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. Blood. 2022;139:3737\u201351.","journal-title":"Blood"},{"key":"6810_CR111","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/blood-2016-06-720433","volume":"129","author":"JA Powell","year":"2017","unstructured":"Powell JA, Lewis AC, Zhu W, Toubia J, Pitman MR, Wallington-Beddoe CT, et al. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood. 2017;129:771\u201382.","journal-title":"Blood"},{"key":"6810_CR112","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/cdd.2017.125","volume":"24","author":"K Brinkmann","year":"2017","unstructured":"Brinkmann K, Grabow S, Hyland CD, Teh CE, Alexander WS, Herold MJ, et al. The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice. Cell Death Differ. 2017;24:2032\u201343.","journal-title":"Cell Death Differ"},{"key":"6810_CR113","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","volume":"37","author":"S Boffo","year":"2018","unstructured":"Boffo S, Damato A, Alfano L, Giordano A. CDK9 inhibitors in acute myeloid leukemia. J Exp Clin Cancer Res. 2018;37:36.","journal-title":"J Exp Clin Cancer Res"},{"key":"6810_CR114","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41420-018-0075-0","volume":"4","author":"AC Lewis","year":"2018","unstructured":"Lewis AC, Wallington-Beddoe CT, Powell JA, Pitson SM. Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies. Cell Death Discov. 2018;4:72.","journal-title":"Cell Death Discov"},{"key":"6810_CR115","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/leu.2009.124","volume":"23","author":"B Falini","year":"2009","unstructured":"Falini B, Bolli N, Liso A, Martelli MP, Mannucci R, Pileri S, et al. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications. Leukemia. 2009;23:1731\u201343.","journal-title":"Leukemia"},{"key":"6810_CR116","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/sj.onc.1205332","volume":"21","author":"H Kiyoi","year":"2002","unstructured":"Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002;21:2555\u201363.","journal-title":"Oncogene"},{"key":"6810_CR117","first-page":"1911","volume":"10","author":"M Nakao","year":"1996","unstructured":"Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911\u20138.","journal-title":"Leukemia"},{"key":"6810_CR118","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","volume":"97","author":"Y Yamamoto","year":"2001","unstructured":"Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434\u20139.","journal-title":"Blood"},{"key":"6810_CR119","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","volume":"25","author":"DA Russler-Germain","year":"2014","unstructured":"Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25:442\u201354.","journal-title":"Cancer Cell"},{"key":"6810_CR120","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nature08617","volume":"462","author":"L Dang","year":"2009","unstructured":"Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739\u201344.","journal-title":"Nature"},{"key":"6810_CR121","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553\u201367.","journal-title":"Cancer Cell"},{"key":"6810_CR122","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/21541248.2017.1339765","volume":"11","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy EJ, Eckfeldt CE. Targeting Ras signaling in AML: RALB is a small GTPase with big potential. Small GTPases. 2020;11:39\u201344.","journal-title":"Small GTPases"},{"key":"6810_CR123","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1182\/blood.V93.6.1817.406k36_1817_1824","volume":"93","author":"M Osato","year":"1999","unstructured":"Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, Okubo T, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1\/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93:1817\u201324.","journal-title":"Blood"},{"key":"6810_CR124","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cell.2017.07.032","volume":"170","author":"L Cimmino","year":"2017","unstructured":"Cimmino L, Dolgalev I, Wang Y, Yoshimi A, Martin GH, Wang J, et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell. 2017;170:1079\u201395.","journal-title":"Cell"},{"key":"6810_CR125","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.beha.2018.09.010","volume":"31","author":"JS Welch","year":"2018","unstructured":"Welch JS. Patterns of mutations in TP53 mutated AML. Best Pr Res Clin Haematol. 2018;31:379\u201383.","journal-title":"Best Pr Res Clin Haematol"},{"key":"6810_CR126","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw4304","volume":"5","author":"JS Jakobsen","year":"2019","unstructured":"Jakobsen JS, Laursen LG, Schuster MB, Pundhir S, Schoof E, Ge Y, et al. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. Sci Adv. 2019;5:eaaw4304.","journal-title":"Sci Adv"},{"key":"6810_CR127","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1182\/blood.V87.6.2171.bloodjournal8762171","volume":"87","author":"L King-Underwood","year":"1996","unstructured":"King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms\u2019 tumor gene WT1 in leukemias. Blood. 1996;87:2171\u20139.","journal-title":"Blood"},{"key":"6810_CR128","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/leu.2009.265","volume":"24","author":"S Abbas","year":"2010","unstructured":"Abbas S, Erpelinck-Verschueren CA, Goudswaard CS, Lowenberg B, Valk PJ. Mutant Wilms\u2019 tumor 1 (WT1) mRNA with premature termination codons in acute myeloid leukemia (AML) is sensitive to nonsense-mediated RNA decay (NMD). Leukemia. 2010;24:660\u20133.","journal-title":"Leukemia"},{"key":"6810_CR129","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ng1156","volume":"34","author":"M Tartaglia","year":"2003","unstructured":"Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34:148\u201350.","journal-title":"Nat Genet"},{"key":"6810_CR130","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1182\/blood-2005-02-0583","volume":"106","author":"J Cammenga","year":"2005","unstructured":"Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W, et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood. 2005;106:3958\u201361.","journal-title":"Blood"},{"key":"6810_CR131","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/sj.onc.1209163","volume":"25","author":"JW Lee","year":"2006","unstructured":"Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene. 2006;25:1434\u20136.","journal-title":"Oncogene"},{"key":"6810_CR132","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N. Engl J Med. 2017;377:454\u201364.","journal-title":"N. Engl J Med"},{"key":"6810_CR133","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","volume":"104","author":"J Lambert","year":"2019","unstructured":"Lambert J, Pautas C, Terre C, Raffoux E, Turlure P, Caillot D, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104:113\u20139.","journal-title":"Haematologica"},{"key":"6810_CR134","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392.","journal-title":"J Clin Oncol"},{"key":"6810_CR135","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","volume":"133","author":"EM Stein","year":"2019","unstructured":"Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133:676\u201387.","journal-title":"Blood"},{"key":"6810_CR136","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135:463\u201371.","journal-title":"Blood"},{"key":"6810_CR137","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1002\/ajh.25238","volume":"93","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol. 2018;93:1301\u201310.","journal-title":"Am J Hematol"},{"key":"6810_CR138","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl J Med. 2019;381:1728\u201340.","journal-title":"N. Engl J Med"},{"key":"6810_CR139","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, Dohner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N. Engl J Med. 2020;383:2526\u201337.","journal-title":"N. Engl J Med"},{"key":"6810_CR140","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","volume":"4","author":"CM Patterson","year":"2021","unstructured":"Patterson CM, Balachander SB, Grant I, Pop-Damkov P, Kelly B, McCoull W, et al. Design and optimisation of dendrimer-conjugated Bcl-2\/x(L) inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021;4:112.","journal-title":"Commun Biol"},{"key":"6810_CR141","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1002\/cam4.3090","volume":"9","author":"H Yi","year":"2020","unstructured":"Yi H, Qiu MZ, Yuan L, Luo Q, Pan W, Zhou S, et al. Bcl-2\/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020;9:4197\u2013206.","journal-title":"Cancer Med"},{"key":"6810_CR142","doi-asserted-by":"publisher","first-page":"e99404","DOI":"10.1371\/journal.pone.0099404","volume":"9","author":"L Bai","year":"2014","unstructured":"Bai L, Chen J, McEachern D, Liu L, Zhou H, Aguilar A, et al. BM-1197: a novel and specific Bcl-2\/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One. 2014;9:e99404.","journal-title":"PLoS One"},{"key":"6810_CR143","doi-asserted-by":"publisher","first-page":"20075","DOI":"10.18632\/oncotarget.24744","volume":"9","author":"P Casara","year":"2018","unstructured":"Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A, et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 2018;9:20075\u201388.","journal-title":"Oncotarget"},{"key":"6810_CR144","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/1538-7445.AM2020-3077","volume":"80","author":"N Hu","year":"2020","unstructured":"Hu N, Guo Y, Xue H, Liu Y, Guo Y, Wang F, et al. Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models. Cancer Res. 2020;80:3077.","journal-title":"Cancer Res"},{"key":"6810_CR145","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3727\/096504020X15825405463920","volume":"28","author":"Q Luo","year":"2020","unstructured":"Luo Q, Pan W, Zhou S, Wang G, Yi H, Zhang L, et al. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res. 2020;28:331\u201344.","journal-title":"Oncol Res"},{"key":"6810_CR146","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1158\/1538-7445.AM2019-2497","volume":"9","author":"S Lin","year":"2019","unstructured":"Lin S, Zhao X, Liu H, Zhang H, Chen Z, Jiang L, et al. FCN-338, a novel and selective Bcl-2 inhibitor, exhibits potent anti-tumor activity in B-cell lymphoma. Cancer Res. 2019;9:2497.","journal-title":"Cancer Res"},{"key":"6810_CR147","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","volume":"3","author":"J Yuda","year":"2023","unstructured":"Yuda J, Will C, Phillips DC, Abraham L, Alvey C, Avigdor A, et al. Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients. Commun Med (Lond). 2023;3:154.","journal-title":"Commun Med (Lond)"},{"key":"6810_CR148","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1158\/1538-7445.AM2021-983","volume":"81","author":"N Bhagwat","year":"2021","unstructured":"Bhagwat N, Grego A, Gowen-MacDonald W, Wang M, Cowart M, Wu X, et al. Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1. Cancer Res. 2021;81:893.","journal-title":"Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06810-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06810-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06810-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T10:02:44Z","timestamp":1718186564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06810-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":148,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["6810"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-06810-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"21 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"413"}}